NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effects of Immulina TM Supplements With PASC Patients

CompletedPhase 3

Sponsor: University of Mississippi Medical Center

Conditions: Post Acute COVID-19 Syndrome

Interventions: Immulina TM, Placebo

Countries: United States, Puerto Rico

This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Males and females, 18 to 99 years old
* If female of child bearing potential, using acceptable means of birth control or postmenopausal for at least two years
* Body temperature between 36.1°C and 37.7°C.
* Has completed the 4-week washout period (if applicable), i.e., has refrained from using internally-consumed dietary supplements prior to Study Day 1 and through the completion of the study
* A minimum of 2 hours fasting (except water) prior to all of the blood draws
* Willing and able (in the opinion of study staff) to comply with all study requirements, including swallowing size 4 capsules (approximately 0.5" long and 0.25" diameter) and having phlebotomy
* Good written and verbal English skills; able to follow instructions (in the investigator's opinion)
* Not participating in a clinical study, currently or within the last 30 days
* Signed informed consent

Exclusion Criteria:

* Pregnant or lactating
* Digestive tract disorders or conditions, such as (but are not limited to): ulcers, ulcerative colitis, Crohn's disease, gastric bypass, colostomy, ischemic colitis, gastroesophageal reflux disease (GERD), irritable bowel disease (IBD), diverticulitis that would be expected to impact on the oral disposition of the Immulina dietary supplement
* Existence of any surgical and/or medical condition, significant disease or disorder, or any finding that may, in the judgment of the investigator, put the volunteer at risk or compromise study participation.
* Any blood-thinning or clotting concomitant medication (prescription anticoagulants)
* Donation or loss of 400 mL or more of blood within 8 weeks of Study Day 1 or unwilling to abstain from donation of blood during the study
* Known or suspected allergy or sensitivity to Immulina, cellulose
* History of drug or alcohol abuse within the last 12 months

Locations (9)

Honolulu, Hawaii, United States
Baton Rouge, Louisiana, United States
New Orleans, Louisiana, United States
Portland, Maine, United States
Jackson, Mississippi, United States
Omaha, Nebraska, United States
Oklahoma City, Oklahoma, United States
Morgantown, Virginia, United States
San Juan, Puerto Rico, Puerto Rico